181 related articles for article (PubMed ID: 27763690)
1. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Koller PB; Kantarjian HM; Nogueras-Gonzalez GM; Jabbour E; Verstovsek S; Borthakur G; Estrov Z; Wierda WG; Garcia-Manero G; Ferrajoli A; Ravandi F; O'Brien SM; Cortes JE
Cancer; 2017 Feb; 123(4):609-616. PubMed ID: 27763690
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
4. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Miranda MB; Lauseker M; Kraus MP; Proetel U; Hanfstein B; Fabarius A; Baerlocher GM; Heim D; Hossfeld DK; Kolb HJ; Krause SW; Nerl C; Brümmendorf TH; Verbeek W; Fauser AA; Prümmer O; Neben K; Hess U; Mahlberg R; Plöger C; Flasshove M; Rendenbach B; Hofmann WK; Müller MC; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R; Saußele S
Leukemia; 2016 Jun; 30(6):1255-62. PubMed ID: 26859076
[TBL] [Abstract][Full Text] [Related]
5. Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India.
Kanakasetty GB; Kuntejowdahalli L; Thanky AH; Dasappa L; Jacob LA; Mallekavu SB; Kumari P
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):52-59. PubMed ID: 27743980
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
Gajendra S; Sharma A; Sharma R; Gupta SK; Sood N; Sachdev R
Turk Patoloji Derg; 2019; 35(1):74-78. PubMed ID: 28272671
[TBL] [Abstract][Full Text] [Related]
7. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
8. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Verma D; Kantarjian H; Strom SS; Rios MB; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; O'Brien S; Cortes J
Blood; 2011 Oct; 118(16):4353-8. PubMed ID: 21846902
[TBL] [Abstract][Full Text] [Related]
9. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
10. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
Di Felice E; Roncaglia F; Venturelli F; Mangone L; Luminari S; Cirilli C; Carrozzi G; Giorgi Rossi P
BMC Cancer; 2018 Nov; 18(1):1069. PubMed ID: 30400842
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE; Özmen D; Öztaş M; Bektaş F; Bayraktar EA; Sadri S; Keskin D; Özgür Yurttaş N; Elverdi T; Salihoğlu A; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):549-557. PubMed ID: 34052176
[TBL] [Abstract][Full Text] [Related]
15. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico.
Ayala M; Ávila E; Domínguez J; Aquino X; Vela J
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):57-62. PubMed ID: 26699851
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
20. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
